ASCO Annual Meeting: Head and Neck | Conference

Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
July 16, 2021

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

Eric J. Sherman, MD, on Immunotherapy Trends in Head and Neck Cancer
July 10, 2021

Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.

Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer
July 07, 2021

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.